Search Results for: FORMULATION DEVELOPMENT TECHNOLOGY A Novel
Articles
FORMULATION DEVELOPMENT TECHNOLOGY - A Novel Drug Delivery System That Offers Zero-Order/Near Zero-Order Release Profile of Low-Dosage Strength Tablets Containing Highly Soluble Actives October 5, 2015
Thomas B. Gold, PhD, was awarded a US patent; the intellectual property centers on formulation development technology that allows for the steady, continuous release of API over a particular duration of time to mitigate variations or spikes in therapeutic benefit.
Quotient Sciences & Intrepid Labs Form Strategic Partnership to Accelerate AI-Guided Formulation Development December 4, 2025
Quotient Sciences and Intrepid Labs recently announced a ground-breaking multi-year strategic partnership to advance the use of artificial intelligence (AI) in...Gelteq Announces New Product Development Agreement With Melbourne Health for Novel Bowel Polyp Growth Reduction Compound October 9, 2025
Gelteq Limited recently announced it has entered into a Product Development and Profit Share Agreement with Melbourne Health, operator of...Roquette Boosts Extensive Cyclodextrins Portfolio With Launch of KLEPTOSE® Crysmeb methyl-beta-cyclodextrin for Oral & Parenteral Formulations October 8, 2025
Roquette, a global leader in plant-based ingredients and pharmaceutical excipients for the health and nutrition sectors, recently launched of its...PRECLINICAL SCREENING PLATFORM - From Preclinical Screening to Clinical Optimization: Accelerating Poorly Soluble Drug Development October 7, 2025
Andrew Parker, PhD, John McDermott, and Sandeep Kumar, PhD, believe the development of poorly soluble drugs remains a significant challenge in pharmaceutical R&D. However, by adopting an adaptive approach that integrates services from preclinical screening to clinical optimization, developers can achieve significant time- and cost-saving benefits.
EXCIPIENT TECHNOLOGY - Driving Oral Drug Delivery Innovation With Safe, Reliable Lipid Excipients October 7, 2025
Nick DiFranco, MEM, says amidst the uncertainty of novel ingredients and formulation techniques, lipid excipients provide a safe, proven platform for enhancing in vivo formulation performance, enabling innovation without sacrificing scalability or regulatory confidence.
Orexo US Awarded $8 Million by BARDA for OX390 Development Partnership September 29, 2025
Orexo AB recently announced its wholly owned US subsidiary, Orexo US, Inc., has been awarded USD 8 million in funding...Arecor Announces Co-Development Agreement With US Insulin Pump Device Company September 25, 2025
Arecor Therapeutics plc has recently signed a co-development agreement with Sequel Med Tech LLC, a company developing state-of-the-art insulin delivery...FORMULATION FORUM - Hot Melt Extrusion – An Enabling Technology for Poorly Soluble Drugs September 8, 2025
Jim Huang, PhD, and Shaukat Ali, PhD, say in spite of many challenges, drug manufactures continue to look for non-conventional, and often novel, polymers to expedite the development of innovative molecules coming out of discovery when none of the conventional technologies do not meet the desired objectives.
FORMULATION DEVELOPMENT - Innovative Drug Delivery Approaches for GLP-1 Agonists: Enhancing Medication Adherence & Treatment Outcomes September 8, 2025
Nasrin Mahmoudi, PharmD, PhD, and Michael Baumann, highlight recent developments in GLP-1 agonist formulations and delivery methods, including advanced injectable formulations, novel oral delivery systems, and topical formulations.
Orexo's AmorphOX Technology May Pave the Way for Intranasal GLP-1 Medication September 5, 2025
Orexo AB recently announced positive pharmacokinetic in-vivo data for a powder-based intranasal semaglutide formulation developed with the AmorphOX technology. In...Quotient Sciences & CPI to Accelerate RNA Drug Development With Joint Venture September 2, 2025
Quotient Sciences, a leading global drug development and manufacturing accelerator, and UK technology innovation centre, CPI, have signed a memorandum...Sever Pharma Solutions Expands Partnership With Silo Pharma on Novel Ketamine-Based Implant for Chronic Pain & Fibromyalgia August 11, 2025
Sever Pharma Solutions, a leading Contract Development and Manufacturing Organization (CDMO) specializing in controlled-release systems for high potent drugs, recently...2025 Respiratory Drug Development e-Book - New Devices & Drugs Enhance Compliance & Facilitate Improved Disease Management July 21, 2025
In this sixth annual Respiratory e-book, learn more about several companies and their contributions to inhalation drug delivery and device design.
FORMULATION FORUM - Manufacturing of Solid Oral Dosage Forms by Direct Compression June 3, 2025
Jim Huang, PhD, and Shaukat Ali, PhD, say not all excipients are well suited for DC, so challenges remain to find excipients compatible to DC due to certain physicochemical properties associated with poor flowability, lack of plasticity, flexibility, and compressibility.
EXECUTIVE INTERVIEW - PCI Pharma Services: Driving Precision, Agility & Partnership in Complex Drug Development May 7, 2025
Anshul Gupte, PhD, RAC Drugs, VP of Pharmaceutical Development at PCI Pharma Services, talks about phase-appropriate development, technical hurdles in pharmaceutical sciences, building agile teams, and what sponsors should prioritize when planning their strategy for novel therapies.
NASAL DRUG DELIVERY - Overcoming the Challenges of Formulation Development May 7, 2025
Eric Kaneps explores the nasal drug delivery landscape, including the benefits of nasal administration compared with other routes and the unique formulation challenges associated with this delivery method.
SPECIAL FEATURE - Bioavailability & Solubility: The Promise of Novel Ingredients April 4, 2025
Contributor Cindy H. Dubin, speaks with several innovating companies to discuss the use of novel excipients as well as other methods and technologies for tackling bioavailability and solubility once and for all.
FORMULATION FORUM - Lymphatic versus Portal Drug Delivery: An Understanding of Drug Oral Absorption & Food Effect April 3, 2025
Jim Huang, PhD, and Shaukat Ali, PhD, say the lymphatic system is a distinctive route that is essential for drug transport and delivery of large and lipophilic molecules by alleviating the challenges in penetrating blood capillaries.
Acumen Pharmaceuticals Announces Topline Results From Phase 1 Study of Subcutaneous Formulation of Sabirnetug March 19, 2025
Acumen Pharmaceuticals, Inc. recently announced topline results from its Phase 1 study comparing pharmacokinetics (PK) between subcutaneous (SC) and intravenous (IV)...
